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Introduction: Obesity increases the risk of death from many adverse 
health outcomes and has also been linked with cancer outcomes. The 
impact of obesity on outcomes of advanced non–small-cell lung can-
cer patients is unclear.
Methods: The authors evaluated the association of body mass index 
(BMI) and outcomes in 2585 eligible patients enrolled in three 
consecutive first-line trials conducted by the Eastern Cooperative 
Oncology Group. BMI was categorized as underweight (BMI < 
18.5 kg/m2), normal weight (BMI: 18.5 to < 25 kg/m2), overweight 
(BMI: 25 to < 30 kg/m2), and obese (BMI ≥ 30 kg/m2). In addition 
to analyzing overall and progression-free survival, reasons for treat-
ment discontinuation were also assessed by BMI group.
Results: Of the patients enrolled, 4.6% were underweight, 44.1% 
were normal weight, 34.3% of patients were classified as overweight, 
and 16.9% were obese. Nonproportional hazards existed for obese 
patients relative to the other three groups of patients, with a change 
in overall survival hazard occurring at approximately 16 months. 
In multivariable Cox models, obese patients had superior outcomes 
earlier on study compared with normal/overweight patients 0.86 
(HR=0.86, p=0.04; 95% CI: 0.75–0.99), but later experienced 
increased hazard (HR=1.54, p< 0.001; 95% CI: 1.22–1.94), indicat-
ing a time effect while undergoing treatment.
Conclusion: Data from these three trials suggest differential out-
comes associated with BMI, and additional studies of the mechanisms 
underlying this observation, as well as dietary and lifestyle interven-
tions, are warranted to help optimize therapy.
Key Words: Body mass index, Weight, Obesity, Non–small-
cell lung cancer, Advanced disease, First-line therapy, Phase III, 
Chemotherapy, Bevacizumab.
(J Thorac Oncol. 2013;8: 1121-1127)
Elevated body mass index (BMI), defined as weight in kilograms divided by the square of the height in meters, 
increases the risk of death from many adverse health out-
comes and continues to remain a significant public health 
problem in developed nations such as the United States, 
Canada, and Europe.1 BMI-defined overweight and obesity, 
which affect nearly two thirds of the U.S. population and con-
tinue to increase in prevalence, are associated with increased 
risk of cardiovascular disease, diabetes, arthritis, and asthma, 
as well as colon, breast, endometrial, and renal cancers.2–6 
With respect to lung cancer, however, many investigations 
have demonstrated an inverse association between BMI and 
risk of fatal lung cancers.7–18
Despite the wealth of literature detailing the association 
between BMI and lung cancer incidence, studies evaluating the 
relationship of BMI on outcomes for patients with lung cancer 
are somewhat limited.19 To our knowledge these studies have not 
focused on lung cancer patients enrolled in clinical trials, which 
select for patients with fewer comorbidities by way of their eli-
gibility criteria; trials typically require good performance status 
(PS), adequate organ function, and limited exposure to major 
surgery or treatments within a reasonable timeframe of study 
entry. Increased BMI has also been associated with improved 
outcomes for patients with renal cell cancer and diffuse large 
B-cell lymphoma, but with poorer prognosis in patients with 
colon, prostate, and breast cancers.3,20–22 It is therefore of inter-
est to study whether or not the association between BMI and 
clinical outcomes can be validated in this setting.
The current study presents results from an analysis of 
the clinical course of advanced non–small-cell lung cancer 
(NSCLC) patients enrolled in the most recent three front-
line phase III trials, E5592, E1594, and E4599, conducted 
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by the Eastern Cooperative Oncology Group (ECOG) in this 
patient population. Statistical endpoints included overall sur-
vival (OS), progression-free survival (PFS), best objective 
response, toxicity, and time to treatment discontinuation. To 
our knowledge, this study is the first to analyze these data 
using prospectively collected treatment and eligibility criteria 
and to include detailed information on underweight patients.
PATIENTS AND METHODS
Study Population
During the period from 1993 to 2004, the ECOG enrolled 
2684 patients to three phase III trials of first-line systemic che-
motherapy for advanced NSCLC. In brief, eligible patients had 
stage IIIB, IV, or recurrent disease, ECOG PS 0 to 1, no prior 
systemic chemotherapy, and adequate bone marrow, hepatic, 
and renal function. Per protocol, all patients were dosed based 
on actual weight. Additional details regarding eligibility, treat-
ment, and results have been reported elsewhere and are sum-
marized in Table 1; E1594 enrolled 65 eligible patients with PS 
2 before a protocol amendment restricted eligibilty to ECOG 
PS of 0 or 1 only.23–25 The primary endpoint of these trials was 
OS, and the primary analyses were conducted among all eli-
gible patients. Each participant gave informed consent. These 
studies were conducted in accordance with the Declaration of 
Helsinki, current Food and Drug Administration Good Clinical 
Practices, and local institutional review board requirements.
Statistical Methods
Baseline patient demographics and disease characteris-
tics were compared using Fisher’s exact test. OS, the primary 
endpoint considered, was defined as time interval in months 
from randomization to death from any cause. PFS was defined 
as the time interval in months from randomization to docu-
mented progression or death. Patients not experiencing an event 
were censored at the last date of follow-up for OS and the last 
date of disease assessment for PFS. Time-to-event distributions 
were estimated using the Kaplan–Meier method, and compari-
sons of these distributions were made using the log-rank test.26 
Multivariable piecewise Cox proportional hazards models were 
used to estimate hazard ratios (HRs) for OS and PFS.27 Response 
and toxicity on protocols E5592 and E1594 were assessed using 
ECOG criteria; for E4599, the Response Evaluation Criteria in 
Solid Tumors version 1.0 and Common Terminology Criteria 
for Adverse Events version 2.0 were used. The cumulative inci-
dence function of time to treatment discontinuation because 
of toxicity, adjustment for death, progression, and withdrawal/
other as competing events was constructed using the method of 
Kalbfleish and Prentice.28 All p values are two-sided, confidence 
intervals (CIs) are at the 95% level, and no adjustments have 
been made for multiple comparisons.
BMI at the time of randomization was defined as weight 
in kilograms divided by the square of the height in meters. 
Patients were stratified into BMI groups defined by the World 
Health Organization: underweight (BMI < 18.5 kg/m2), nor-
mal weight (BMI: 18.5 to < 25 kg/m2), overweight (BMI: 25 
to < 30 kg/m2), and obese (BMI ≥ 30 kg/m2).20,29
RESULTS
At a median follow-up of 64.9 months, 2585 of the 2684 
patients (96.3%) randomized on these trials were declared eli-
gible and constituted the primary analysis population; all had 
BMI measurements at the time of study registration. Table 2 
displays the baseline patient demographics and disease char-
acteristics of the study cohort by BMI group. Consistent with 
the general population, 4.6% of patients were underweight, 
44.1% were normal weight, 34.3% of patients were classified 
as overweight, and 16.9% were obese. Most of the baseline 
demographics and disease characteristics were significantly 
imbalanced by BMI group, with the exception of stage, his-
tology, prior surgery, pleural involvement, liver metastases, 
and baseline serum albumin. Underweight patients were more 
likely to be younger, African American, female, have worse 
ECOG PS, have more weight loss and radiotherapy before 
study enrollment, and be enrolled on the more recent trials.
Figure 1 displays the results of the OS analysis by BMI 
group. Of 2585 patients, 2353 (91%) had died at the time of 
this analysis. The median OS estimated among underweight 
patients was 7.0 months (95% CI: 5.5–9.6), among normal-
weight patients was 8.6 months (95% CI: 8.0–9.4), among 
overweight patients was 9.3 months (95% CI: 8.6–10.1), and 
among obese patients was 11.0 months (95% CI: 10.2–11.9). 
TABLE 1.  Eastern Cooperative Oncology Phase III First-Line Trials in Advanced Non–Small-Cell Lung Cancer, 1993–2004
Study Regimens Accrual 
Period
No. of Patients 
with BMI Data
E5592: Bonomi et al., 2000 Cisplatin (75 mg/m2) + etoposide (100 mg/m2) 1993–94 574
Cisplatin (75 mg/ m2) + paclitaxel (250 mg/m2)
Cisplatin (75 mg/ m2) + paclitaxel (135 mg/m2)
E1594: Schiller et al., 2002 Cisplatin (75 mg/ m2) + paclitaxel (135 mg/m2) 1996–99 1161
Cisplatin (100 mg/ m2) + gemcitabine (1000 mg/ m2)
Cisplatin (75 mg/ m2) + docetaxel (75 mg/ m2)
Carboplatin, AUC 6.0 mg/ml/min + paclitaxel (225 mg/ m2)
E4599: Sandler et al. 2006 Carboplatin, AUC 6.0 mg/ml/min + paclitaxel  
(200 mg/m2) + bevacizumab (15 mg/kg)
2001–04 850
Carboplatin, AUC 6.0 mg/ml/min + paclitaxel (200 mg/m2)
AUC, area under the curve; BMI, body mass index.
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A logrank test for differences in these four OS distributions 
was statistically significant (p = 0.005), though it is impor-
tant to note that there was no statistically significant differ-
ence in OS between normal-weight and overweight patients 
(p = 0.11). Visual inspection of the OS Kaplan–Meier curves 
as well as a formal test for proportional hazards using a test 
based on Schoenfeld residuals leads to the conclusion that 
nonproportional hazards exist for obese patients relative to 
TABLE 2.  Distribution of Baseline Patient Demographics and Disease Characteristics by BMI
Underweight Normal Weight Overweight Obese
BMI < 18.5 kg/m2 18.5 ≤ BMI < 25 kg/m2 25 ≤ BMI < 30 kg/m2 BMI ≥ 30 kg/m2 Total
(n = 123) (n = 1139) (n = 887) (n = 436) (N = 2585)
Protocol (p = 0.004)
  E5592 34 27.6% 276 24.2% 191 21.5% 73 16.7% 574 22.2%
  E1594 59 48.0% 514 45.1% 391 44.1% 197 45.2% 1161 44.9%
  E4599 30 24.4% 349 30.6% 305 34.4% 166 38.1% 850 32.9%
Age (p = 0.003)
  Median (range) 59 35–83 61 29–85 62 25–86 63 31–88 62 25–88
Race (p = 0.01)
  White 94 76.4% 971 85.5% 779 87.8% 376 86.4% 2220 86.0%
  Black 21 17.1% 93 8.2% 62 7.0% 33 7.6% 209 8.1%
  Other 8 6.5% 72 6.3% 46 5.2% 26 6.0% 152 5.9%
Sex (p = 0.001)
  Male 58 47.2% 678 59.5% 572 64.5% 249 57.1% 1557 60.2%
  Female 65 52.8% 461 40.5% 315 35.5% 187 42.9% 1028 39.8%
ECOG PS (p < 0.001)
  0 27 22.0% 347 30.6% 336 37.9% 163 37.5% 873 33.9%
  1 89 72.4% 761 67.0% 532 60.0% 259 59.5% 1641 63.6%
  2 7 5.7% 27 2.4% 18 2.0% 13 3.0% 65 2.5%
Prior weight loss (p < 0.001)
  <5% 44 35.8% 697 61.2% 687 77.5% 366 83.9% 1794 69.4%
  ≥5% 79 64.2% 441 38.8% 200 22.5% 70 16.1% 790 30.6%
  Unknown 1 1
Stage (p = 0.13)
  IIIB 11 8.9% 152 13.3% 114 12.9% 68 15.6% 345 13.4%
  IV 97 78.9% 839 73.7% 647 73.0% 294 67.4% 1877 72.6%
  Recurrent 15 12.2% 148 13.0% 125 14.1% 74 17.0% 362 14.0%
Histology (p = 0.43)
  Squamous 16 13.0% 161 14.2% 120 13.5% 58 13.3% 355 13.7%
  Adenocarcinoma 66 53.7% 693 60.9% 548 61.8% 277 63.5% 1584 61.3%
  Other 41 33.3% 283 24.9% 219 24.7% 101 23.2% 644 24.9%
Prior RT (p = 0.02)
  Yes 25 20.3% 234 20.5% 143 16.1% 67 15.4% 469 18.2%
  No 98 79.7% 905 79.5% 743 83.9% 368 84.6% 2114 81.8%
Prior surgery (p = 0.84)
  Yes 42 34.4% 415 36.6% 319 36.1% 166 38.2% 942 36.6%
  No 80 65.6% 719 63.4% 564 63.9% 268 61.8% 1631 63.4%
Pleura involvement (p = 0.94)
  Yes 37 30.1% 352 30.9% 263 29.7% 131 30.0% 783 30.3%
  No 86 69.9% 787 69.1% 624 70.3% 305 70.0% 1802 69.7%
Liver mets (p = 0.19)
  Yes 30 24.4% 237 20.8% 164 18.5% 80 18.3% 511 19.8%
  No 93 75.6% 902 79.2% 723 81.5% 356 81.7% 2074 80.2%
Serum Albumin (p = 0.89)
  Median (range) 3.6 2.1–5.1 3.7 0–8.4 3.8 1.7–8.2 3.9 2.1–5.0 3.8 0–8.4
BMI, body mass index; ECOG, Eastern Oncology Group; PS, performance status; RT, radiotherapy.
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the other three groups of patients; specifically, the hazard for 
obese patients seems to begin increasing at approximately 16 
months postrandomization.30–32 At this timepoint, a total of 
656 patients remained in follow-up: 23 underweight patients, 
266 normal-weight patients, 225 overweight patients, and 142 
obese patients. To account for this in the analysis of OS, piece-
wise Cox models estimating the HR of obese patients rela-
tive to the combined group of normal-weight and overweight 
patients adjusting for time as a time-varying covariate were 
fitted, stratified by protocol to account for any potential trends 
in BMI over time, as well as protocol effects; the HR com-
paring underweight patients with normal-weight/overweight 
patients was also estimated. In a model unadjusted for other 
baseline prognostic factors, the estimated OS HR comparing 
underweight patients with normal-weight/overweight patients 
was 1.26 (p = 0.01; 95% CI: 1.05–1.51); the estimated OS HR 
comparing obese patients whose days on study was less than 16 
months from randomization with normal-weight/overweight 
patients was 0.81 (p = 0.001; 95% CI: 0.71–0.92). When time 
on study exceeded 16 months, obese patients experienced a 
significant increase in their OS hazard rate relative to normal-
weight/overweight patients, with an estimated OS HR of 1.31 
(p = 0.02; 95% CI: 0.62–0.95). After adjusting for sex (female 
versus male, HR = 0.83; p < 0.001), ECOG PS (1/2 versus 
0; HR = 1.40; p < 0.001), stage (IV/recurrent versus IIIB; 
HR = 1.37; p < 0.001), presence of liver metastases (HR = 
1.39; p < 0.001), weight loss (>5% in the previous 6 months; 
HR = 1.26; p < 0.001), and elevated baseline albumin (>3.8; 
HR = 0.67; p < 0.001), all of which were chosen using backward 
stepwise selection and statistically significant, the estimated 
OS HR comparing underweight patients with normal-weight/
overweight patients was 1.12 (p = 0.29; 95% CI: 0.91–1.37), 
and comparing obese patients whose days postregistration 
were less than 16 months with normal-weight/overweight 
patients was 0.86 (p = 0.04; 95% CI: 0.75–0.99). When time 
on study exceeded 16 months, obese patients experienced a 
significant increase in their OS hazard rate relative to normal-
weight/overweight patients, with an estimated OS HR of 1.54 
(p < 0.001; 95% CI: 1.22–1.94).
At the time of last follow-up, 2503 patients (97%) had 
experienced a PFS event. The median PFS estimated among 
underweight patients was 2.7 months (95% CI: 2.0–4.0), 
among normal-weight patients was 3.9 months (95% CI: 3.6–
4.3), among overweight patients was 4.4 months (95% CI: 
4.2–4.8), and among obese patients was 5.1 months (95% CI: 
4.5–5.7). A logrank test for differences in these four PFS distri-
butions was statistically significant (p = 0.001); the results are 
displayed in Figure 2. In an unadjusted Cox model stratified 
on protocol, the estimated PFS HR comparing underweight 
patients with normal-weight/underweight patients was 1.19 
(p = 0.06; 95% CI: 0.99–1.43); comparing obese patients 
with normal-weight/underweight patients, the estimated PFS 
HR was 0.85 (p = 0.002; 95% CI: 0.76–0.94). After adjusting 
for the same prognostic variables included in the multivari-
able OS Cox models (sex [HR = 0.91; p = 0.03], ECOG PS 
[HR = 1.24; p < 0.001], stage [HR = 1.42; p < 0.001], pres-
ence of liver metastases [HR = 1.19; p = 0.002], weight loss 
[HR = 1.21; p < 0.001], and elevated baseline albumin [HR = 
0.76; p < 0.001]), the adjusted HRs were 1.04 (p = 0.73; 95% 
CI: 0.85–1.27) for underweight patients and 0.92 (p = 0.13; 
95% CI: 0.82–1.03) for obese patients, when comparing each 
of these two groups with normal-weight/overweight patients.
We next assessed the best objective response rates for 
patients treated on these three protocols across the four BMI 
groups. Among underweight patients, the response rate was 
13.8% compared with 20.5% among normal-weight patients, 
22.5% among overweight patients, and 21.3% among obese 
patients (p = 0.15). There were also no significant differences 
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observed in the rates of grade 3 or higher hematological tox-
icities across BMI groups: 39.3%, 45.1%, 44.6%, and 40.0% 
within the underweight, normal-weight, overweight, and 
obese groups, respectively (p = 0.20). Similarly, there were 
no significant imbalances observed in the rates of grade 3 or 
higher nonhematological toxicities: 61.5%, 62.4%, 62.2%, 
and 67.4% within the underweight, normal-weight, over-
weight, and obese groups, respectively (p = 0.24).
We next explored the time to treatment discontinua-
tion to assess whether or not the differences in outcome by 
BMI group could be explained in part by protocol compli-
ance. The 15-month point estimates for the cumulative inci-
dence rates and their corresponding standard deviations are 
reported beneath the cumulative incidence curves in Figure 3. 
The percentage of patients discontinuing treatment because 
of progression or death was highest among underweight 
patients (52.3%) and decreased with BMI to 42.3% among 
obese patients; the rate of discontinuation because of patient 
withdrawal and other reasons followed a similar inverse trend 
with BMI. The rate of treatment discontinuation per protocol 
increased with BMI; however, it was estimated to be 9.2% 
among underweight patients and increased to 17.0% among 
obese patients. Obese patients were also more likely to discon-
tinue treatment because of adverse events (23.0%) than those 
with lower BMI, with a rate of 16.8% among underweight 
patients. In a regression model of subdistribution functions 
in competing risks, these results were significantly different 
across BMIs (p = 0.004).
DISCUSSION
In this retrospective analysis of 2585 patients with 
advanced NSCLC enrolled in three ECOG clinical trials, 
we assessed the relationship between BMI and clinical out-
comes. In multivariable models, obese patients had signifi-
cantly different OS when compared with normal-weight and 
overweight patients; however, their risk of death from any 
cause increased dramatically once they had been on study 
longer than 16 months. This indicates that the protective 
effect of obesity in lung cancer patients is for a limited time, 
after which the ultimate impact of obesity on survival from 
all causes supersedes. Though not statistically significant, 
there was a trend toward worse outcomes for underweight 
patients when compared with normal-weight/overweight 
patients.
These results are consistent with the limited number of 
previous studies evaluating the role of BMI on outcomes for 
NSCLC patients and on risk of lung cancer, but this report 
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addresses several of the limitations of previous analyses by 
including prospectively defined and collected study data, 
uniform staging, and preselection of patients with good PS, 
cardiac/organ function, and otherwise lower symptom burden 
and complicating comorbid illness. In our study, we have also 
evaluated the reasons why patients stopped protocol treat-
ment by BMI group, and found that the outcomes associ-
ated with higher BMI occur in accordance with lower rates 
of withdrawal from study and despite a higher rate of treat-
ment discontinuation because of toxicity. One reason for this 
observation may be the differential pharmacokinetics result-
ing in higher chemotherapy dosing among BMI groups; how-
ever, it is also possible that patients with lower BMI at the 
time of enrollment have more aggressive disease and worse 
nutritional status, subjecting them to more cachexia and sub-
sequently more rapid cancer cell growth.
The time dependence of obesity on outcome relative to 
patients with normal-weight or underweight status at the time 
of diagnosis is an interesting observation. One biological rea-
son contributing to this observation may lie in the synergy 
that exists between peroxisome proliferator–activated receptor 
ligands, which include natural compounds such as fatty acids 
and antidiabetic drugs, and platinum-based agents, which has 
been shown to increase the efficacy of platinum by as much as 
fourfold in preclinical studies.33 Because second-line therapies 
for advanced NSCLC do not include platinum agents as stan-
dard of care, the rapid decline in obese patients late in their 
course of follow-up on these trials could be attributed to the 
absence of cisplatin or carboplatin after progression, thereby 
decreasing the synergy with peroxisome proliferator–activated 
receptor ligands. Other research has implied that metabolic 
drugs such as phenformin and metformin induce apoptosis in 
liver kinase B1 (LKB1)-deficient NSCLC; given that LKB1 
is inactivated approximately 20% of NSCLC, and that obese 
patients have a reasonable likelihood of receiving antidia-
betic drugs, the superior outcomes early on in their course of 
cancer treatment could be driven largely by interactions with 
these concomitant medications. We unfortunately do not have 
details on the prevalence of diabetes, concomitant medications, 
or on differences in treatment at progression, to address these 
hypotheses.33–35 It is important to note that our results contradict 
evidence that insulin-like growth factor 1 (IGF-1), a hormone 
associated with obesity, promotes tumor growth.36
A limitation of our study is that smoking status, a con-
founding variable known to be associated with lower BMI, was 
not collected on any of these clinical trials, but it was recently 
reported that residual confounding because of smoking sta-
tus did not contribute to the inverse relationship between BMI 
and risk of lung cancer in a prospective cohort study.7 Despite 
eligibility criteria that select for good-prognosis patients, we 
do not have details on patient comorbidities, which may super-
sede the effects of treatment, expose the patients to excess risk 
later in their disease trajectory, and thereby explain the change 
in hazard for obese patients.
Our results are consistent with observational studies 
demonstrating an inverse association between BMI and risk 
of fatal lung cancers, as well as with outcomes for patients 
with lymphoma and renal cancer.7–18,20,21 This obesity paradox 
has also been described in other areas of medicine includ-
ing acute lung injury, septic shock, heart failure, and Human 
Immunodeficiency Virus.37–40 Because obesity is associated 
with more comorbidities and other adverse health conditions, 
the inverse association between BMI and survival seems intui-
tively discordant; one explanation for this may be in how our 
studies and others have defined being overweight and obese. 
BMI is a numerical measure of both fat mass and muscle 
mass, and is therefore not the most accurate measure of body 
fat. Other methods of evaluating true body fat, such as waist 
circumference and weight to height ratio, as well as cardiore-
spiratory and muscular fitness have suggested an important 
role in the obesity paradox, but these methods were unfortu-
nately not available for analysis in our study.41
The ideal situation would be conducting an analysis 
of serial weight measurements over the entire postrandom-
ization timeframe, because the rapid decline of the obese 
patients could be because they lose so much weight that they 
become normal-weight or underweight at that point in time. 
Unfortunately, these data are not available for our studies. 
This type of information is traditionally collected on treatment 
forms, which are submitted at each treatment cycle while a 
patient remains on protocol treatment.
A limitation of our analysis is that some of the treat-
ment regimens were administered for as short a timeframe as 
six cycles of 3 weeks each or until documented disease pro-
gression, at which time protocol therapy would be discontin-
ued and treatment forms would no longer be collected—this 
is actually fairly standard for clinical trials reporting. With a 
median PFS of approximately 4 months in this population, this 
leaves us with scarce data to conduct a robust analysis of BMI 
over time until death. It is important to note, however, that 
analyses of weight change over time do not allow for clinical 
decision making about best course of therapy for patients at 
baseline, when they present with untreated metastatic disease. 
That being said, weight gain has been shown to be an impor-
tant factor in outcomes for patients with locally advanced 
NSCLC, and serial weight measurements may inform other 
studies, such as those on renal function.42–44
In summary, higher BMI among patients with advanced 
NSCLC enrolled in three National Cancer Institute–funded 
Cooperative Group clinical trials is associated with signifi-
cantly differential survival; however, further studies of the 
mechanisms underlying this observation, as well as dietary 
and lifestyle interventions, are warranted to help optimize 
therapy.
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